Evidence map›Paper›PMID 40594067›Full record

ArticleScientific reports2025

Choroidal evaluation of FTLD-Tau and biomarker-determined Alzheimer's disease.

Benjamin J Kim, Tomas S Aleman, Katheryn A Q Cousins, Ebenezer Daniel, Eli Smith, Emma Iacobucci, Anton Kolomeyer, Christopher K Hwang, Corey T McMillan, Vivianna M Van Deerlin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Benjamin J KimScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA. benjamin.kim@pennmedicine.upenn.edu.
Tomas S AlemanScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Katheryn A Q CousinsFrontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ebenezer DanielScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Eli SmithScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Emma IacobucciScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Anton KolomeyerScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Christopher K HwangScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Corey T McMillanFrontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Vivianna M Van DeerlinDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey S PhillipsFrontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yinxi YuScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
Gui-Shuang YingScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, 51 North 39th Steet, Philadelphia, PA, 19104, USA.
David J IrwinFrontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI CLAIRE H MITCHELL · 1985 to 2026
$19.5M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
Human Retinal Imaging Biomarkers for FTLD-Tau in Relation to FTLD-TDP and Nonamnestic ADRF1AG083774 · NIA · UNIVERSITY OF PENNSYLVANIA · PI KIM, BENJAMIN J. · 2023 to 2023
$2.1M
NEI NIH HHS P30 EY001583NIA NIH HHS R01 AG054519NIA NIH HHS RF1 AG083774
6 · The paper itself

Abstract

Frontotemporal lobar degeneration with tauopathy (FTLD-Tau) can present clinically similar to Alzheimer's disease but lacks a biomarker. Alzheimer's disease has been associated with choroidal thinning compared to controls. We compared the choroid of 25 probable FTLD-Tau (pFTLD-Tau) patients (42 eyes), 26 biomarker-determined probable Alzheimer's disease neuropathologic change (pADNC) patients (49 eyes), and 53 normal controls (80 eyes). Cerebrospinal fluid biomarkers determined presence of ADNC. All pFTLD-Tau patients had a syndrome highly associated with FTLD-Tau. Optical coherence tomography was performed with masked manual choroidal thickness (CT) measurements. With Image J, binarized images determined the choroidal vascularity index (CVI). Linear regression with generalized estimating equations to account for inter-eye correlation was performed. For pFTLD-Tau, pADNC, and controls, the subfoveal CT was 308.9, 286.0, and 301.5 μm, and CVI was 0.72, 0.72, and 0.73, respectively (all p > 0.05 for each group comparison). Adjusting for demographics, the CT and CVI were not significantly different between groups, including 13 CT measurement locations (all p > 0.05). Among pADNC patients, an exploratory analysis found a correlation between CVI and disease duration (Pearson r = 0.32, p = 0.04). We found no significant difference of CT or CVI between pFTLD-Tau, pADNC, and controls. Additional studies are warranted to evaluate how CVI relates to ADNC.

Indexed as

Alzheimer DiseaseChoroidFrontotemporal Lobar DegenerationAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle Agedtau ProteinsTomography, Optical CoherenceBiomarkerstau Proteins

Identifiers

PMID40594067
PMCPMC12216448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.